Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

aaaaas Aug. 3 at 9:39 PM

$SRPT by the book, will be down to $12 after earnings

2 · Reply

KingTut Aug. 3 at 9:35 PM

$SRPT peekaboo

1 · Reply

KingTut Aug. 3 at 8:14 PM

$SRPT im seeing estimates all over the place. not sure which is acurate.

1 · Reply

KingTut Aug. 3 at 8:09 PM

$SRPT 2026 rev estimates are 1.2-1.4b... not 1.8b.

2 · Reply

Princeredyr Aug. 3 at 8:06 PM

$SRPT I’ve been tortured by this stock that 7 percent does nothing to excite me .

2 · Reply

Sareptaking Aug. 3 at 8:03 PM

$SRPT good day but long way to go here 🥱

0 · Reply

LudwigVanBeethoven Aug. 3 at 7:59 PM

$SRPT saved the 15 mark ..

0 · Reply

thewolfny Aug. 3 at 7:55 PM

$SRPT lfg i got in last week at 15.22 avg and sweated it down ... lets put the shorts to the grindstone ... i know this post has no intrinsic value, but it feels good to write!

0 · Reply

Fred_Sigma_Invest Aug. 3 at 7:40 PM

$SRPT $25.01

3 · Reply

Kuato_Lives Aug. 3 at 7:38 PM

$SRPT Jumped back in 3k shares @15 bucks. Up on the day at least. One and only day ill be in the green ha.

0 · Reply

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-27T14:50:34.000Z - 7 days ago

Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts

Jul 27, 2026, 9:19 AM EDT - 7 days ago

Sarepta names former Abbvie president as CEO as Ingram retires

2026-07-27T12:35:41.000Z - 7 days ago

Sarepta appoints Severino as Chief Executive Officer

Jul 27, 2026, 8:30 AM EDT - 7 days ago

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

Jul 22, 2026, 8:30 AM EDT - 12 days ago

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

2026-07-21T10:31:15.000Z - 13 days ago

Citi sees intensifying competition for Sarepta from Dyne Therapeutics

DYN

Jul 13, 2026, 9:46 AM EDT - 21 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)

2026-07-09T11:15:12.000Z - 25 days ago

Sarepta price target lowered to $20 from $23 at Piper Sandler

2026-07-08T21:10:22.000Z - 26 days ago

Sarepta upgraded to Outperform from Peer Perform at Wolfe Research

2026-07-01T10:20:36.000Z - 4 weeks ago

H.C. Wainwright says Sarepta news does not signal full approvals

2026-06-30T12:35:47.000Z - 4 weeks ago

Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53

Jun 30, 2026, 8:30 AM EDT - 4 weeks ago

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

Jun 8, 2026, 10:40 AM EDT - 2 months ago

Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Sarepta Therapeutics Transcript: AGM 2026

Jun 1, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

2026-05-15T12:30:23.000Z - 2 months ago

Sarepta price target lowered to $19 from $20 at Evercore ISI

May 13, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

2026-05-07T00:41:58.000Z - 3 months ago

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:05 PM EDT - 3 months ago

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Sarepta Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

2026-04-16T16:20:19.000Z - 3 months ago

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

2026-04-07T15:08:48.000Z - 4 months ago

Sarepta price target raised to $19 from $18 at RBC Capital

Mar 25, 2026, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics Slides: Study result

Mar 25, 2026, 8:05 AM EDT - 4 months ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 4 months ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 19, 2026, 8:30 AM EDT - 4 months ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 5 months ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 3, 2026, 1:50 PM EST - 5 months ago

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 9:00 AM EST - 5 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:05 AM EST - 5 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 4:30 PM EST - 5 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:05 PM EST - 5 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 5 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 8:53 AM EST - 6 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:10 AM EST - 6 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 6 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 6 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 12, 2026, 12:00 PM EST - 7 months ago

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 7 months ago

Sarepta Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:58 AM EST - 7 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 7 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 7 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 8 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 8:57 AM EST - 8 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 9 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 2:54 PM EST - 9 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 9 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 9:55 AM EST - 9 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 9 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 4:27 AM EST - 9 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 9 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:24 PM EST - 9 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 9 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 10 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 10 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 3, 2025, 8:30 AM EDT - 10 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 11 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 25, 2025, 3:11 AM EDT - 1 year ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

aaaaas Aug. 3 at 9:39 PM

$SRPT by the book, will be down to $12 after earnings

2 · Reply

KingTut Aug. 3 at 9:35 PM

$SRPT peekaboo

1 · Reply

KingTut Aug. 3 at 8:14 PM

$SRPT im seeing estimates all over the place. not sure which is acurate.

1 · Reply

KingTut Aug. 3 at 8:09 PM

$SRPT 2026 rev estimates are 1.2-1.4b... not 1.8b.

2 · Reply

Princeredyr Aug. 3 at 8:06 PM

$SRPT I’ve been tortured by this stock that 7 percent does nothing to excite me .

2 · Reply

Sareptaking Aug. 3 at 8:03 PM

$SRPT good day but long way to go here 🥱

0 · Reply

LudwigVanBeethoven Aug. 3 at 7:59 PM

$SRPT saved the 15 mark ..

0 · Reply

thewolfny Aug. 3 at 7:55 PM

$SRPT lfg i got in last week at 15.22 avg and sweated it down ... lets put the shorts to the grindstone ... i know this post has no intrinsic value, but it feels good to write!

0 · Reply

Fred_Sigma_Invest Aug. 3 at 7:40 PM

$SRPT $25.01

3 · Reply

Kuato_Lives Aug. 3 at 7:38 PM

$SRPT Jumped back in 3k shares @15 bucks. Up on the day at least. One and only day ill be in the green ha.

0 · Reply

nyzgujuboi89 Aug. 3 at 7:22 PM

$SRPT 17-18 before earnings would be golden! And then 30-40+% up after earnings!

0 · Reply

LudwigVanBeethoven Aug. 3 at 7:13 PM

$SRPT silently watching .. grrrr and brrrrr

0 · Reply

deweyeggbert Aug. 3 at 7:07 PM

$SRPT grab em up. $30 in the blink of an eye.

0 · Reply

AGI2018 Aug. 3 at 6:59 PM

$SRPT is their projected 2026 revenue of 1.8B realistic?

1 · Reply

drbrain00 Aug. 3 at 6:46 PM

$SRPT Only fear is that new CEO uses this as a kitchen sink quarter to flush out the junk. With us already at lows,,we can’t afford it

1 · Reply

DebbyEsther Aug. 3 at 6:43 PM

$SRPT is hovering near 52-week lows ahead of Aug 5 earnings. With FDA sNDAs accepted (PDUFA Feb 28, 2027) and competitor setbacks, ELEVIDYS stands as the sole approved DMD gene therapy, supporting a projected $1.8B+ annual run-rate backed by solid 3-year EMBARK data. Extreme oversold conditions alongside regulatory exclusivity create a compelling asymmetrical risk-reward setup for a potential valuation reset. Are you playing the $SRPT turnaround before earnings or waiting on the sidelines?

0 · Reply

BrittonHickman Aug. 3 at 6:42 PM

$SRPT positions like these… it’s where men are made.

0 · Reply

Astronaut_Trades Aug. 3 at 6:13 PM

$SRPT interesting divergence from $XBI

2 · Reply

jm0olah Aug. 3 at 6:00 PM

$SRPT the only insane post earnings price action will be if it stays flat at 15-16

0 · Reply

greko50 Aug. 3 at 5:52 PM

$SRPT The bar has never been lower heading into 2Q ER, with a mc of 1.62 bil. Barring an absolute collapse in Elevidys/PMO revs, with no new safety issues, this should move higher from these levels. Markets can overshoot in both directions, hence the recent drop below $15. If nothing has fundamentally changed, I consider these moves opportunities to take advantage of overall poor macro environment as the main contributing factor. Looking forward to the EC with our new CEO at the helm......

1 · Reply

KingTut Aug. 3 at 3:04 PM

$SRPT trying.

0 · Reply

ErikaMartinez426 Aug. 3 at 2:19 PM

$USAR $IBIT $SRPT $DELL $BRK.A USAR remains execution-driven, iShares Bitcoin Trust provides regulated Bitcoin exposure, Sarepta advances genetic medicine, Dell benefits from AI infrastructure, and Berkshire Hathaway offers diversified long-term value.

0 · Reply

Market Cap	1.57B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	24.31
Forward PE	4.00
Profit Margin	-32.45%
Debt to Equity Ratio	0.56

Volume	3,798,800
Avg Vol	3,409,944
Day's Range	N/A - N/A
Shares Out	105.58M
Stochastic %K	58%
Beta	0.21
Analysts	Sell
Price Target	$21.83